Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that newer generation anticholinergics with improved side-effect profiles and less-frequent daily dosing schedules will grow the urinary incontinence (UI) market to reach $2.5 billion in 2011.
"Newer generation extended-release anticholinergics such as Pharmacia's Detrol LA and Alza's Ditropan XL offer improved side-effect profiles and less- frequent daily dosing schedules," said Kat Neumeyer, analyst at Decision Resources. "These attributes will improve patient compliance with UI therapies and help to counteract the typically high discontinuation rate for anticholinergics."
The report also found that novel agents introduced to the stress incontinence market will offer an alternative to surgery.
"The stress urinary incontinence (SUI) market is woefully underserved in terms of drug therapeutics," said Ms. Neumeyer. "Physicians are eager for pharmacotherapies that would adequately address mild to moderate stress urinary incontinence symptoms, and Eli Lilly's Cymbalta is poised to be that drug of choice. However, surgical treatment will continue to be the most widely used treatment for SUI."
Disease Background-Urinary Incontinence
Urinary incontinence (UI) is the involuntary loss of urine that is objectively demonstrable and poses a social or hygiene problem for the patient. Although UI affects early 115 million people in the seven major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), the majority of sufferers have not sought medical attention for the problem. Those patients that do find their way into the drug-treated population have historically faced myriad problems associated with administration of and compliance with existing drug therapies.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Urinary Incontinence is a Mosaic report.
About Decision Resources
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
Web site: http://www.dresources.com/